To further validate our hits and provide ready-to-trial drugs capable of stopping viral infection/replication of current and future variants, we screened a number of FDA-approved drugs for unrelated diseases and chemical compounds reported to interfere with the most common viral host factor candidates (SLC7A11, RIPK4, and MASTL). This evidence concerns the gene MASTL and viral infectious disease.